Start Date
May 31, 2019
Primary Completion Date
November 30, 2021
Study Completion Date
May 31, 2022
Mirvetuximab Soravtansine
The dose will not be recalculated unless the patient has ±10% weight change.
Bevacizumab
Subject will receive IMGN853 first followed by bevacizumab. There is no planned delay between the IMGN853 and bevacizumab administration.
Stephenson Cancer Center, Oklahoma City
Collaborators (1)
ImmunoGen, Inc.
INDUSTRY
University of Oklahoma
OTHER